Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ZMDPX
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
ITcetuximab
|
|||||
| Synonyms |
ITcetuximab; IT cetuximab
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Lung cancer [ICD11:2C25]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1-2
|
|||||
| Antibody Name |
Cetuximab
|
Antibody Info | ||||
| Antigen Name |
Epidermal growth factor receptor (EGFR)
|
Antigen Info | ||||
| Payload Name |
Saporin
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Tumor Growth Inhibition value (TGI) |
≈ 85
|
%
|
A-549 cells
|
Lung adenocarcinoma
|
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 85.00% (Day 16) | Positive EGFR expression (EGFR +++/++) | ||
| Method Description |
Mice were injected intraperitoneally with 3 mg/kg of ITcetuximab, and 2days later,2 h after the administration of NPe6 (5 mg/kg) via the tail vein, the tumors were irradiated with a 664 nm laser at a dose of 30 J/cm2 from the diode laser unit.
|
||||
| In Vivo Model | A549 CDX model | ||||
| In Vitro Model | Lung adenocarcinoma | A-549 cells | CVCL_0023 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.36 nM | High EGFR expression (EGFR +++) | ||
| Method Description |
Cancer cell lines were incubated with compounds for 72 h. IC50 was evaluated from the sigmoid curve obtained using the curvefitting tool of the ImageJ software.
|
||||
| In Vitro Model | Skin squamous cell carcinoma | A-431 cells | CVCL_0037 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.77 nM | Positive EGFR expression (EGFR +++/++) | ||
| Method Description |
Cancer cell lines were incubated with compounds for 72 h. IC50 was evaluated from the sigmoid curve obtained using the curvefitting tool of the ImageJ software.
|
||||
| In Vitro Model | Lung adenocarcinoma | A-549 cells | CVCL_0023 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 10.00 nM | Low EGFR expression (EGFR +) | ||
| Method Description |
Cancer cell lines were incubated with compounds for 72 h. IC50 was evaluated from the sigmoid curve obtained using the curvefitting tool of the ImageJ software.
|
||||
| In Vitro Model | Invasive breast carcinoma | MCF-7 cells | CVCL_0031 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.